


GLP-1 Drug Market to reach USD 42.0 Billion by 2035 at 13.17% CAGR

GLP-1 Drug Market to Surge from USD 12.19 Billion in 2025 to USD 42.0 Billion by 2035-Powered by Rising Obesity and Diabetes Prevalence, Long-Acting Formulation

NY, CA, UNITED STATES, August 24, 2026 /EINPresswire.com/ -- As per Market Research Future, the [global GLP-1 Drug Market size](#) is projected to reach USD 42.0 Billion by 2035 from USD 12.19 Billion in 2025, at a CAGR of 13.17% during the forecast period 2025–2035. The market base was estimated at USD 10.77 Billion in 2024.



GLP-1 Drug Market Size Share

The 13.17% CAGR—anchored by structural shifts in metabolic disease management—is propelled by three converging forces: the rising global prevalence of obesity and type 2 diabetes, with over 830 million people worldwide living with diabetes in 2022, driving healthcare providers to increasingly adopt GLP-1 receptor agonists for superior glycemic control, sustained weight reduction, and long-term cardiovascular risk management; advancements in drug formulations, particularly long-acting injectables and oral delivery methods, which significantly improve patient adherence and convenience; and the integration of digital health technologies, including mobile applications and telehealth services, that enhance patient monitoring, engagement, and treatment outcomes.

Global pharmaceutical companies and health organizations are amplifying this momentum. Novo Nordisk generated approximately DKK 290.4 billion in 2024 revenue, reflecting strong investment in innovative metabolic disease therapies. Eli Lilly reported approximately USD 45.0 billion in 2024 revenue, supporting development of convenient long-acting and oral treatment options. According to WHO data, over 830 million people worldwide were living with diabetes in 2022, while IHME data shows high body mass index contributes to more than 160 million disability-adjusted life years (DALYs) globally. These forces are creating the clinical infrastructure

and patient demand on which the GLP-1 Drug Market depends.

Request A Free Sample:

https://www.marketresearchfuture.com/sample_request/22011

Key Market Trends & Growth Drivers

Rising Demand for Weight Management Solutions

The market is witnessing an increasing demand for medications that assist in weight management. As obesity rates continue to rise globally, more individuals are seeking effective pharmacological interventions. This trend indicates a shift in consumer attitudes towards proactive health management, with GLP-1 drugs being recognized for their dual benefits of weight loss and glycemic control. Novo Nordisk continues advancing product development through next-generation GLP-1 therapies while strengthening strategic partnerships supporting obesity management research.

Advancements in Drug Formulations

Innovations in drug formulations are becoming a hallmark of the industry. Pharmaceutical companies are exploring various delivery methods, including long-acting injectables and oral formulations. These advancements aim to enhance patient compliance and convenience, potentially leading to better health outcomes and increased market penetration. Long-acting GLP-1 formulations accounted for approximately 57% of market revenue in 2024, driven by improved adherence and once-weekly dosing convenience.

Integration of Digital Health Technologies

The incorporation of digital health technologies into the industry is gaining traction. Tools such as mobile applications and telehealth services are being utilized to monitor patient progress and facilitate communication between healthcare providers and patients. Sanofi continues investing in connected diabetes care and digital therapeutic ecosystems, generating approximately EUR 41.8 billion in 2024 sales.

Increasing Prevalence of Obesity and Diabetes

The rising incidence of obesity and diabetes is a primary driver. According to WHO, approximately 422 million people worldwide are living with diabetes, with obesity being a significant risk factor. The market is projected to expand as healthcare providers increasingly prescribe GLP-1 medications to manage chronic conditions. The World Health Organization has identified obesity as a global epidemic, underscoring the urgent need for innovative solutions.

Ask for Customization:

Market Segment Insights

BY TYPE

Long-acting: Largest segment with 57% share in 2024, driven by prolonged effects and minimized patient dosing frequency. Novo Nordisk continues expanding long-acting GLP-1 therapies through sustained product innovation.

Short-acting: Fastest-growing segment, appealing to patients seeking flexibility and rapid glycemic control.

Dual-action: Positioned as a novel entry catering to multifaceted therapeutic needs.

BY DISTRIBUTION CHANNEL

Retail Pharmacies: Largest segment, benefiting from traditional consumer trust and accessibility. Eli Lilly continues strengthening retail pharmacy distribution through portfolio expansion.

Hospital Pharmacies: Significant share at 46% in 2024, due to partnerships with healthcare providers and direct access to patients requiring specialized treatment.

Online Pharmacies: Fastest-growing channel, gaining traction among tech-savvy consumers seeking convenience and lower prices.

BY INDICATION

Type 2 Diabetes: Largest segment with 52% share in 2024, due to high prevalence and increasing awareness of chronic disease management.

Obesity: Fastest-growing indication, as the global obesity epidemic continues to escalate, leading to more treatment solutions being developed for weight management.

Cardiovascular Diseases: Smaller but significant share, reflecting a more specialized approach in GLP-1 drug applications.

BY ADMINISTRATION ROUTE

Subcutaneous Injection: Dominant route with 64% share in 2024, offering robust efficacy and established preference among healthcare providers.

Oral: Fastest-growing route, positioning itself as an appealing alternative for patients seeking

less invasive options.

Read Detailed Insights:

<https://www.marketresearchfuture.com/reports/glp-1-drug-market-22011>

Regional Outlook

North America — Market Leader in Innovation

North America leads with over 50.14% of global revenue in 2024, generating around USD 5.4 Billion. The region's growth is driven by increasing diabetes prevalence, rising healthcare expenditure, and favorable reimbursement policies. According to CDC, approximately 38.4 million Americans are living with diabetes, while nearly 97.6 million adults have prediabetes. The competitive landscape is characterized by continuous innovation and strategic partnerships among leading pharmaceutical companies.

Europe — Second Largest Market

Europe was valued at USD 3.23 billion in 2024, representing the second-largest regional market with a 30% share. The region benefits from increasing awareness of diabetes management and supportive healthcare policies. Regulatory bodies like the EMA are actively facilitating the approval of new therapies. Leading countries include Germany, France, and the UK, where major pharmaceutical companies such as Sanofi and AstraZeneca are heavily invested.

Asia-Pacific — Rapidly Growing Market Segment

The Asia-Pacific region accounts for about 15% of the global share. The growth is driven by rising diabetes rates, urbanization, and increasing healthcare access. Countries like China and India are experiencing a surge in demand, supported by government initiatives aimed at improving healthcare infrastructure. The competitive landscape is evolving with companies like Boehringer Ingelheim and AstraZeneca leading the charge.

Middle East and Africa — Untapped Potential

The MEA region holds around 5% of the global share, driven by increasing awareness of diabetes and obesity, coupled with rising healthcare investments. Countries like South Africa and the UAE are leading the way, with a growing presence of international pharmaceutical companies.

Competitive Landscape and Recent Developments

The GLP-1 drug market is characterized by intense competition and rapid growth, driven by increasing prevalence of diabetes and obesity worldwide. The global industry appears moderately fragmented, with several key players exerting significant influence.

KEY COMPANIES AND RECENT MILESTONES

Novo Nordisk (DK): Generated approximately DKK 290.4 billion in 2024 revenue. Continues advancing next-generation GLP-1 therapies and strengthening strategic partnerships supporting obesity management research.

Eli Lilly (US) (August 2025): Announced a collaboration with a leading technology firm to integrate artificial intelligence into its drug development processes. Reported approximately USD 45.0 billion in 2024 revenue.

Sanofi (FR) (September 2025): Launched a new GLP-1 drug specifically targeting the Asian market, reflecting its commitment to regional expansion. Generated approximately EUR 41.8 billion in 2024 sales.

Other Key Players: Boehringer Ingelheim (DE), AstraZeneca (GB), Merck & Co. (US), Bristol-Myers Squibb (US), Amgen (US).

Future Outlook: 2025–2035

The GLP-1 Drug Market is projected to reach USD 42.0 billion by 2035, growing at a CAGR of 13.17%, driven by increasing diabetes prevalence, rising obesity rates, and advancements in drug formulations.

New opportunities lie in:

Expansion into emerging markets with tailored GLP-1 therapies

Development of combination therapies to enhance efficacy

Investment in digital health platforms for patient engagement

By 2035, the GLP-1 Drug Market is expected to achieve substantial growth and innovation.

More Related Research Insights:

<https://www.marketresearchfuture.com/reports/thoracic-surgery-market-27902>

<https://www.marketresearchfuture.com/reports/orthodontic-supplies-market-7364>

<https://www.marketresearchfuture.com/reports/ozempic-market-43226>

<https://www.marketresearchfuture.com/reports/remote-patient-monitoring-market-10905>

<https://www.marketresearchfuture.com/reports/automatic-pill-dispenser-market-8008>

<https://www.marketresearchfuture.com/reports/3d-bioprinting-market-869>

<https://www.marketresearchfuture.com/reports/cell-based-assays-market-9126>

<https://www.marketresearchfuture.com/reports/leukemia-therapeutics-market-7425>

<https://www.marketresearchfuture.com/reports/bioreactor-market-43158>

<https://www.marketresearchfuture.com/reports/antibody-drug-conjugate-market-1113>

Larry Wilson

WantStats Research And Media Pvt. Ltd.

+1 855-661-4441

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[YouTube](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/936563544>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.